Leveraging the past to illuminate longevity for the future

Rooted in Amish genetic knowledge, Zoe Biosciences’ novel platform could become the gold standard for delayed aging.

With an eye fixed firmly on the future, Zoe Biosciences positions itself as developing longevity therapeutics for the 21st century. ‘Zoe’, of course, means ‘life’, and by tackling age-related diseases and aging itself (when the FDA allows), the company, which is helmed by CEO Scott Gies, is hoping to extend both lifespan and healthspan.

My take on this: However, if you think about the 21st century, cutting edge research and groundbreaking science, then it is unlikely that the Amish community will also leap into your mind – but, by evaluating the genes of people whose traditions are rooted in the past, Zoe Biosciences is spearheading technology for the future.

We sat down with Zoe’s CEO Scott Gies to find out more about the origin of the company and its plans for the future.

Zoe’s platform is built on an ‘Amish mutation’ which is one of the most intriguing backstories we’ve come across. In 2015, Dr Doug Vaughan, a cardiologist and now the company’s CSO, was presented with a young woman from Berne, Indiana, who was suffering from a rare bleeding disorder.

For Gies and the rest of the Zoe team, the potential upside to human healthspan is not only vast, but already genetically validated in humans, rather than in animal models that attempt to replicate human aging.

Discover more about Zoe Biosciences, their groundbreaking Amish genetic research and explore their upcoming endeavors in the quest for slowing down the aging process HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!